Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Diffuse large B cell lymphoma: A study of second primary malignancies among adults in the United States

View Full Paper
Ask AI
Bookmark
Share

Authors

OOOboseh John OgedegbeACAsfand Yar CheemaAOAyobami Gbenga Olafimihan

Discussion

Loading...

Member takes

Overview

Analysis finds increased second primary malignancies in adults with DLBCL, suggesting extensive monitoring is needed.

Key Points

  • Second primary malignancies significantly increase in diffuse large B cell lymphoma patients, indicating critical follow-up is essential.
  • Among 134,366 DLBCL cases analyzed, 9,893 had second primary malignancies, highlighting this serious complication.
  • Assessment using the SEER database revealed an O/E ratio of 1.29 for secondary malignancies, showing a high incidence of risk.
  • Findings suggest close screening for second primary malignancies is warranted for DLBCL survivors due to higher mortality risks.

Cite This Study

Ogedegbe et al. (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d4bdhttps://doi.org/10.1182/blood-2025-3680
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Risk of second primary malignancies among CLL survivors across treatment eras: A SEER-based study with racial and ethnic stratification2025
  2. 2Risk of second primary hematological malignancy post chimeric antigen receptor T-cell therapy in diffuse large B-cell lymphoma: Propensity-matched analysis using trinetx database2025
  3. 3Patient characteristics, healthcare resource utilization and costs across treatment lines in diffuse large B-cell lymphoma - a German claims data study.2025 · 1 citations
  4. 4Prognostic factors in diffuse large B cell lymphoma: a retrospective analysis from a tertiary center2025
  5. 5Outcomes of patients with dual primary T-cell and B-cell lymphoid malignancies2025